The PredART study—published in the New England Journal of Medicine—showed that a four-week course of moderate dose prednisone reduced the risk of TB-IRIS by 30% in HIV-positive patients at high risk.
Small change, huge impact: how an existing drug may change TB patients’ lives.
Older patients and those with lower body weight may need to be carefully monitored during linezolid treatment.
Community stakeholders representing various Khayelitsha-based organisations gathered to consult with CIDRI-Africa’s clinical research team on future tuberculous meningitis research.
+27 (0)21 406 6797
Institute of Infectious Disease
and Molecular Medicine
University of Cape Town
Supported by the Wellcome Trust (203135/Z/16/Z)